Investment Thesis
Panacea Life Sciences is in severe financial distress with negative stockholders equity of -$9.6M, indicating technical insolvency. The company is burning cash with -$357.1K operating cash flow, maintains only $107.6K in cash reserves, and has critically low liquidity ratios (0.23x current ratio). While gross margins of 63.1% suggest viable product economics, the company cannot sustain operations at its current trajectory.
Strengths
- Decent gross margin of 63.1% indicates reasonable product pricing and cost structure
- Net loss improved 12.3% YoY showing trajectory toward reduced losses
- Operating in medicinal chemicals sector with established market demand
Risks
- Negative stockholders equity of -$9.6M reflects technical insolvency from balance sheet perspective
- Critical cash shortage with only $107.6K on hand insufficient for continued operations
- Negative operating cash flow of -$357.1K indicates company is burning cash every period
- Severe liquidity crisis: current ratio of 0.23x and quick ratio of 0.03x preclude debt service
- Minimal revenue base of $1.1M with only 3.7% YoY growth insufficient to achieve profitability
- Data freshness issue: latest available data from March 31, 2024 (nearly 2 years old)
Key Metrics to Watch
- Cash balance and runway to insolvency
- Operating cash flow trajectory and path to profitability
- Revenue growth acceleration and operating leverage
- Stockholders equity recovery and balance sheet stabilization
Financial Metrics
Revenue
1.1M
Net Income
-1.4M
EPS (Diluted)
$-0.09
Free Cash Flow
-362.1K
Total Assets
17.4M
Cash
107.6K
Profitability Ratios
Gross Margin
63.1%
Operating Margin
-100.1%
Net Margin
-136.9%
ROE
N/A
ROA
-8.3%
FCF Margin
-34.3%
Balance Sheet & Liquidity
Current Ratio
0.23x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
155.3%
Interest Coverage
-2.46x
Long-term Debt
100.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T09:42:18.933082 |
Data as of: 2024-03-31 |
Powered by Claude AI